TScan Therapeutics (NASDAQ:TCRX) Given Outperform Rating at Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating restated by Wedbush in a research report issued to clients and investors on Wednesday,RTT News reports. They presently have a $7.00 price target on the stock. Wedbush’s target price suggests a potential upside of 236.54% from the company’s previous close.

A number of other brokerages have also recently issued reports on TCRX. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Needham & Company LLC dropped their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday.

TScan Therapeutics Trading Up 8.3 %

Shares of TCRX stock opened at $2.08 on Wednesday. TScan Therapeutics has a 12-month low of $1.82 and a 12-month high of $9.69. The company has a market capitalization of $111.01 million, a PE ratio of -1.96 and a beta of 0.91. The firm has a 50 day moving average price of $2.43 and a two-hundred day moving average price of $4.04. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

A number of institutional investors have recently modified their holdings of TCRX. State Street Corp raised its stake in TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after purchasing an additional 148,414 shares in the last quarter. abrdn plc raised its position in shares of TScan Therapeutics by 137.8% in the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after buying an additional 512,049 shares in the last quarter. Geode Capital Management LLC raised its position in shares of TScan Therapeutics by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock valued at $4,849,000 after buying an additional 72,967 shares in the last quarter. Stifel Financial Corp lifted its holdings in shares of TScan Therapeutics by 3.9% during the 3rd quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after acquiring an additional 3,733 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of TScan Therapeutics during the 3rd quarter worth approximately $112,000. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.